{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:37:47Z","timestamp":1762875467342},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12185-012-1154-2","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T12:24:01Z","timestamp":1343737441000},"page":"380-382","source":"Crossref","is-referenced-by-count":4,"title":["Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura"],"prefix":"10.1007","volume":"96","author":[{"given":"V.","family":"Noronha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. D.","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM198904133201505","volume":"320","author":"T Gernsheimer","year":"1989","unstructured":"Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320:974\u201380.","journal-title":"N Engl J Med"},{"key":"1154_CR2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","volume":"102","author":"M Chang","year":"2003","unstructured":"Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, Nugent DJ. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887\u201395.","journal-title":"Blood"},{"key":"1154_CR3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1532\/IJH97.04168","volume":"81","author":"R McMillan","year":"2005","unstructured":"McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol. 2005;81:94\u20139.","journal-title":"Int J Hematol"},{"key":"1154_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI113060","volume":"80","author":"PJ Ballem","year":"1987","unstructured":"Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33\u201340.","journal-title":"J Clin Invest"},{"key":"1154_CR5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","volume":"34","author":"DB Cines","year":"2002","unstructured":"Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;34:995\u20131008.","journal-title":"N Engl J Med"},{"key":"1154_CR6","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00043426-200308000-00017","volume":"25","author":"LJ Butros","year":"2003","unstructured":"Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenicpurpura: a retrospective analysis. J Pediatr Hematol Oncol. 2003;25:660\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1154_CR7","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2004-12-4598","volume":"106","author":"DB Cines","year":"2005","unstructured":"Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106:2244\u201351.","journal-title":"Blood"},{"key":"1154_CR8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","volume":"357","author":"JB Bussel","year":"2007","unstructured":"Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237\u201347.","journal-title":"N Engl J Med"},{"key":"1154_CR9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","volume":"373","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641\u20138.","journal-title":"Lancet"},{"key":"1154_CR10","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood.V112.11.3432.3432","volume":"112","author":"JB Bussel","year":"2008","unstructured":"Bussel JB, Cheng G, Saleh MN, Meddeb B, Bailey C, Stone N, Aivado M. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood. 2008;112:3432.","journal-title":"Blood"},{"key":"1154_CR11","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood.V112.11.3431.3431","volume":"112","author":"JB Bussel","year":"2008","unstructured":"Bussel JB, Psaila B, Saleh MN, Vasey S, Mayer B, Stone N, Arning M. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood. 2008;112:3431. (abstract 3431).","journal-title":"Blood"},{"key":"1154_CR12","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","volume":"357","author":"JG McHutchinson","year":"2007","unstructured":"McHutchinson JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227\u201336.","journal-title":"N Engl J Med"},{"key":"1154_CR13","first-page":"761","volume":"15","author":"A Baranwal","year":"2007","unstructured":"Baranwal A, Fraser L, Jayawardene D, Jagiello-Gruszfeld A, Bondarenko I, Mendoza J. Efficacy and safety of eltrombopag, a novel, oral platelet growth factor on platelet counts in patients with cancer receiving carboplatin\/paclitaxel chemotherapy. Support Care Cancer. 2007;15:761. (abstract P-168).","journal-title":"Support Care Cancer"},{"key":"1154_CR14","doi-asserted-by":"crossref","first-page":"e2012003","DOI":"10.4084\/mjhid.2012.003","volume":"4","author":"A Khalafallah","year":"2012","unstructured":"Khalafallah A, Rahman Z, Ogden K, Hannan T. Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia. Mediterr J Hematol Infect Dis. 2012;4:e2012003.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1154_CR15","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.4081\/hr.2011.e20","volume":"3","author":"E Vlachaki","year":"2011","unstructured":"Vlachaki E, Papageorgiou V, Klonizakis F, Spandonidou M, Chisan S, Vetsiou E, et al. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Rep. 2011;3:e20.","journal-title":"Hematol Rep"},{"key":"1154_CR16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag\u00a0for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377:393\u2013402.","journal-title":"Lancet"},{"key":"1154_CR17","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","volume":"100","author":"DJ Kuter","year":"2002","unstructured":"Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457\u201369.","journal-title":"Blood"},{"key":"1154_CR18","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/sj.onc.1205323","volume":"21","author":"K Kaushansky","year":"2002","unstructured":"Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002;21:3359\u201367.","journal-title":"Oncogene"},{"key":"1154_CR19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0014-5793(95)01072-M","volume":"374","author":"Y Ezumi","year":"1995","unstructured":"Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonist-induced aggregation in platelets in vitro. FEBS Lett. 1995;374:48\u201352.","journal-title":"FEBS Lett"},{"key":"1154_CR20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1182\/blood.V94.4.1273","volume":"94","author":"P Rojnuckarin","year":"1999","unstructured":"Rojnuckarin P, Drachman JG, Kaushansky K. Thrompoietin-induced activation of the mitogenactivated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood. 1999;94:1273\u201382.","journal-title":"Blood"},{"key":"1154_CR21","doi-asserted-by":"crossref","first-page":"13480","DOI":"10.1074\/jbc.274.19.13480","volume":"274","author":"JG Drachman","year":"1999","unstructured":"Drachman JG, Millet KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not Tyk2. J Biol Chem. 1999;274:13480\u20134.","journal-title":"J Biol Chem"},{"key":"1154_CR22","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/0091270010383019","volume":"51","author":"S Hayes","year":"2011","unstructured":"Hayes S, Ouellet D, Zhang J, Wire MB, Gibiansky E. Population PK\/PD modeling of\u00a0eltrombopag\u00a0in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol. 2011;51:1403\u201317.","journal-title":"J Clin Pharmacol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1154-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1154-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1154-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T04:15:23Z","timestamp":1594527323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1154-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1154-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,1]]}}}